Abstract

BackgroundThe diagnostic accuracy of Cancer Differentiation Analysis (CDA) Technology has beenevaluated and verified in previous studies (Abstract No. e12578, e22171, e12587, and e15059). The aim of this study is to investigate the potential capability of CDA technology for breast cancer prognosis. 

Methods:  Blood samples (n = 45) collected from 3 breast cancer cases during the course of post-operative treatment (POT) were tested by CDA technology. Information of the cases includes clinical stage, histology, treatment protocols (TP) and so on. Due to the small sample size and different clinical conditions, data were analyzed individually. Based on the time of POT, CDA data for each case were grouped into 3 categories, before, during and after POT. The average CDA values were calculated and compared with different treatment effect evaluation (TEE) (table 1). CDA value ≥ 50 (rel. units) indicates high risk region, and 44 – 50 (rel. units) suggests region for close follow-up.

 Results: Case A endured three TP, including four cycles of second-line chemotherapy, two cycles of endocrine therapy and five cycles of GP regimen because of repeated PD evaluation from 3/12/2014 to 2/1/2015, although a brief PR was reported after the second second-line chemotherapy. The average CDA of this case was 51.33 before and 56.98 after POT. Case B had five cycles of DX regimen between 8/29/2014 and 12/26/2014, and her TEE was PR after two cycles of DX regimen. Her average CDA was 55.30 before and 50.45 after POT. Case C had four cycles of DC regimen and twiceantibody trastuzumab. Her average CDA was 58.16 before and 48.80 after POT. 
Conclusions: CDA values appear to be declined after POT if the individuals show favorable response to the treatment, but remain high post-operative if the individuals do not respond well to POT. These preliminary data suggest that CDA technology may be useful for monitoring breast cancer patient’s response to POT. More studies are needed to validate our findings.

• ASCO Annual Meeting 2016. New Targets and New Technologies. Category : Tumor Biology. Session Type and Session Title: This abstract will not be presented at the 2016 ASCO Annual Meeting but has been published in conjunction with the meeting. Abstract Number: E23176.
  Author(s): Hongmei Tao, Yue Lin, Xuedong Du, Xing Tang, Da Lou, Chris Chang Yu; AnPac Bio-Medical Science and Technology Co., LTD, Shanghai, China; Anpac Bio-Medical Science Technology Co., Ltd., Shanghai, China; Anpac Bio-Medical Science Co Ltd, Shanghai, China